Cantargia AB (publ) (CANTA.ST) News
Track canonical SquawkNews coverage tagged to CANTA.ST, Cantargia AB (publ). This hub brings together deduplicated headlines about stockholm, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Cantargia highlights AACR preclinical data for nadunolimab plus ras inhibition in PDAC
Cantargia said preclinical data presented at AACR supports nadunolimab combined with ras inhibition in PDAC, citing two approaches acting on non-overlapping parts of PDAC biology and impacts on the tumor microenvironment
EQUITY | Sep 30, 2026, 05:11 AM UTC
M
Cantargia to run Phase 1b/2a trial of nadunolimab plus a RAS inhibitor in pancreatic cancer
Cantargia said it has preclinical data, presented at AACR Conference on Pancreatic Cancer, supporting nadunolimab with RAS inhibition in pancreatic ductal adenocarcinoma and plans a Phase 1b/2a trial.
EQUITY | Sep 30, 2026, 05:06 AM UTC